MTOR and neoplasm: In our prior work, senescence and upregulation of genes in the PI3K/AKT/mTOR pathway were observed in triple-negative breast cancer (TNBC) patient-derived xenograft models treated with alisertib to resistance, and tumor growth inhibition was demonstrated in those models treated with alisertib and sapanisertib in combination [13].